Depressive disorder is associated with a significant burden and costs to the society and patients. Remission of depressive disorder is achieved in only one-third of the patients after the first antidepressant trial.
The present article provides a summary of the therapeutic pharmacological and neurostimulation strategies that have been evaluated for treatment-resistant depression.